CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones
The primary objective of this study is to compare overall survival (OS) in participants receiving xaluritamig plus abiraterone against investigator's...
Phase 3
Berlin, Germany and 59 other locations
with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm)....
Phase 3
Berlin, Germany and 321 other locations
This is a phase III, randomized, open-label, multi-center study to assess the efficacy of treatment intensification with docetaxel plus apalutamide a...
Phase 3
Berlin, Germany and 55 other locations
The purpose of this study is to evaluate the efficacy and safety of apalutamide in adult men with high-risk non-metastatic castration-resistant prostate...
Phase 3
Berlin, Germany and 378 other locations
survival (rPFS) per 1) Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 for soft tissue and/or Prostate Cancer Wo...
Phase 3
Berlin, Germany and 322 other locations
The main objective of the study is to compare overall survival in participants receiving xaluritamig versus investigator's choice (cabazitaxel or sec...
Phase 3
Berlin, Germany and 163 other locations
The purpose of the study is to assess and evaluate dosimetry, safety, and tolerability following administration of up to 12 cycles of (177Lu) vipivot...
Phase 1
Berlin, Germany and 20 other locations
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer.BCR means tha ...
Phase 3
Berlin, Berlin, Germany and 236 other locations
hormonal therapy (NHT) in men with metastatic castration-resistant prostate cancer (mCRPC) who have previously been treated with on ...
Phase 3
Berlin, Germany and 279 other locations
Researchers are looking for new ways to treat metastatic castration-resistant prostate cancer (mCRPC). Researchers have designed a ...
Phase 3
Berlin, Germany and 262 other locations
Clinical trials
Research sites
Resources
Legal